Sean Harper - Amgen Insider

AMGN -- USA Stock  

USD 186.19  0.20  0.11%

Executive Vice President - Research and Development

Dr. Sean E. Harper is the Executive Vice President Research and Development of Amgen Inc. Dr. Harper joined the Company in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety
Age: 53  President Since 2012  Ph.D    
805-447-1000  http://www.amgen.com
Harper served as Senior Vice President, Global Development and Corporationrationrationrate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.

Sean Harper Latest Insider Activity

Sean Harper over two months ago via Macroaxis 
Sale by Sean Harper of 1525 shares of Amgen
Sean Harper over three months ago via Macroaxis 
Sale by Sean Harper of 1525 shares of Amgen
Sean Harper over three months ago via Macroaxis 
Sale by Sean Harper of 1525 shares of Amgen
Sean Harper over three months ago via Macroaxis 
Payment of 1034 shares by Sean Harper of Amgen subject to Rule 16b-3

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jan LundbergEli Lilly and Company
2010
Carrie NicholEndo International plc
2018
Richard DeLucaMerck Co
2011
Shannon HallBio Rad Laboratories
2014
Terrance CarlsonMallinckrodt Public Limited Com
2015
Roger PerlmutterMerck Co
2013
Francis CussBristol Myers Squibb Company
2013
Barton PetersonEli Lilly and Company
2009
Murdo GordonBristol Myers Squibb Company
2016
Shawn SoderbergBio Rad Laboratories
2013
Joshua SmileyEli Lilly and Company
2018
Alfonso ZuluetaEli Lilly and Company
2017
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Jeffrey SimmonsEli Lilly and Company
2008
Samuel MoedBristol Myers Squibb Company
2012
Louis SchmuklerBristol Myers Squibb Company
2017
Stephen FussellAbbott Laboratories
2013
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Julie GerberdingMerck Co
2016
Paul SilvaVertex Pharmaceuticals Incorpor
2011
Timothy ErnstBio Rad Laboratories
2016

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.